BRIEF published on 05/14/2025 at 22:20, 1 year 4 months ago Bausch Health annonce les résultats des élections et les approbations lors de son assemblée annuelle 2025 Bausch Santé Vote Des Actionnaires Élection Du Directeur Assemblée Annuelle Approbation De L'indemnisation
BRIEF published on 05/14/2025 at 22:20, 1 year 4 months ago Bausch Health Announces Election Results and Approvals at 2025 Annual Meeting Bausch Health Annual Meeting Shareholder Vote Director Election Compensation Approval
PRESS RELEASE published on 05/14/2025 at 22:15, 1 year 4 months ago Bausch Health Announces 2025 Annual Meeting of Shareholder Results Bausch Health Companies Inc. announces election of 10 directors at 2025 annual meeting of shareholders and various approvals and appointments Shareholders Bausch Health Companies Inc. Compensation Annual Meeting Election Of Directors
BRIEF published on 05/06/2025 at 14:05, 1 year 4 months ago Xifaxan Reduces Risk of 30-Day Rehospitalization After OHE XIFAXAN Chronic Liver Disease OHE Rehospitalization Claims-Based Analysis Lactulose
BRIEF published on 05/06/2025 at 14:05, 1 year 4 months ago Xifaxan réduit le risque de réhospitalisation dans les 30 jours suivant une OHE XIFAXAN Maladie Chronique Du Foie Lactulose Réhospitalisation OHE Analyse Basée Sur Les Réclamations
PRESS RELEASE published on 05/06/2025 at 14:00, 1 year 4 months ago Xifaxan(R) (rifaximin) Treatment Following Overt Hepatic Encephalopathy (OHE) Hospitalization Associated with Reduced Risk of 30-Day OHE Rehospitalization New analysis shows Xifaxan efficacy in reducing OHE rehospitalizations regardless of prior treatment. Data presented at DDW 2025 XIFAXAN Bausch Health Gastroenterology OHE Rehospitalizations
BRIEF published on 04/30/2025 at 22:10, 1 year 4 months ago Bausch Health Reports First-Quarter 2025 Results Financial Results EBITDA Revenue Growth Bausch Health First Quarter 2025
BRIEF published on 04/30/2025 at 22:10, 1 year 4 months ago Bausch Health publie ses résultats du premier trimestre 2025 Résultats Financiers EBITDA Croissance Des Revenus Bausch Santé Premier Trimestre 2025
PRESS RELEASE published on 04/30/2025 at 22:05, 1 year 4 months ago Bausch Health Announces First Quarter 2025 Results Bausch Health Companies Inc. reports strong first quarter 2025 financial results with revenue growth, successful refinancing, and favorable court ruling. Company remains focused on profitable growth and shareholder value Financial Results Revenue Growth Shareholder Value Bausch Health First Quarter 2025
BRIEF published on 04/29/2025 at 14:05, 1 year 4 months ago Bausch Health Secures Health Canada Approval for Thermage FLX Thermage FLX Bausch Health Health Canada Aesthetic Technology Skin Tightening
Published on 09/21/2026 at 15:45, 2 hours 31 minutes ago Datavault AI and Cutting-Edge Sports Management Announce Dream Bowl XV at AT&T Stadium and Launch First-of-Its-Kind Bowl Combine
Published on 09/21/2026 at 14:20, 3 hours 56 minutes ago Doctor's Choice(R) Clinically-Proven Scrubs Launching on Amazon Canada
Published on 09/21/2026 at 14:05, 4 hours 11 minutes ago Winners of this Year's Semmelweis-Richter International Journalism Award Announced
Published on 09/21/2026 at 14:00, 4 hours 16 minutes ago Dateline Files Motion to Resume Operations at Colosseum
Published on 09/21/2026 at 13:45, 4 hours 31 minutes ago Nine Mile Metals DDH WD-26-11 Intersects 2 High Grade VMS Zones Over 27.6M Including 3.08% CU-EQ Over 10.70M, 3.27% CU-EQ Over 9.30M and 4.30% CU-EQ Over 5.0M
Published on 09/21/2026 at 18:00, 16 minutes ago Cham Swiss Properties places bond of CHF 100 million
Published on 09/21/2026 at 17:45, 31 minutes ago EQS-Adhoc: Airbus reports share buyback transactions 11-18 September 2026
Published on 09/21/2026 at 17:45, 31 minutes ago Charwood Energy poursuit sur un rythme de croissance élevé. Chiffre d’affaires semestriel en hausse de +43 % à 5,6 M€.
Published on 09/21/2026 at 17:45, 31 minutes ago Charwood Energy continues to grow at a strong pace. H1 revenue up +43% to €5.6m.
Published on 09/21/2026 at 17:00, 1 hour 16 minutes ago Menarini Group and NewAmsterdam Pharma Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination)
Published on 09/21/2026 at 18:01, 15 minutes ago Partnership agreement signed between Manitou Group and HD Construction Equipment
Published on 09/21/2026 at 17:46, 30 minutes ago WEB SA - STATUTORY HALF-YEAR RESULTS AS OF 30/06/2026
Published on 09/21/2026 at 17:46, 30 minutes ago WEB SA - RESULTATS SEMESTRIELS STATUTAIRES AU 30/06/2026
